A role for antiangiogenic therapy in breast cancer

被引：16

作者：

Moses M.A. ^{[1
]}

Harper J. ^{[1
]}

Fernández C.A. ^{[1
]}

机构：

[1] Vascular Biology Program, Children's Hospital, Boston, MA 02115

来源：

Current Oncology Reports | 2004年 / 6卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Breast Cancer; Vascular Endothelial Growth Factor; Tamoxifen; Bevacizumab; Trastuzumab;

D O I：

10.1007/s11912-996-0008-6

中图分类号：

学科分类号：

摘要：

The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical trials that antiangiogenesis can be an important strategy in the treatment of cancer. This report reviews the contemporary therapeutic approaches for breast cancer, the essential role that angiogenesis plays in the initiation and progression of this disease, and the strategies that should be considered to make antiangiogenic therapy a successful component of breast cancer treatment. Copyright © 2004 by Current Science Inc.

引用

页码：42 / 48

页数：6

共 61 条

[11]

Tamoxifen for early breast cancer: An overview of the randomised trials, Lancet, 351, pp. 1451-1467, (1998)

[12]

Fisher B., Dignam J., Wolmark N., Et al., Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J. Natl. Cancer Inst., 89, pp. 1673-1682, (1997)

[13]

Fisher B., Redmond C., Legault-Poisson S., Et al., Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16, J. Clin. Oncol., 8, pp. 1005-1018, (1990)

[14]

Saphner T., Tormey D.C., Gray R., Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer, J. Clin. Oncol., 9, pp. 286-294, (1991)

[15]

Fornander T., Rutqvist L.E., Cedermark B., Et al., Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers, Lancet, 1, pp. 117-120, (1989)

[16]

Shushan A., Peretz T., Uziely B., Et al., Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer, Am. J. Obstet. Gynecol., 174, pp. 141-144, (1996)

[17]

Powles T.J., Hickish T., Kanis J.A., Et al., Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women, J. Clin. Oncol., 14, pp. 78-84, (1996)

[18]

Pritchard K.I., Paterson A.H., Paul N.A., Et al., Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer, J. Clin. Oncol., 14, pp. 2731-2737, (1996)

[19]

Shapiro C.L., Manola J., Leboff M., Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer, J. Clin. Oncol., 19, pp. 3306-3311, (2001)

[20]

Peters W., Rosner G., Vrendenburgh J., Et al., A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13, Proc. ASCO, 18, (1999)

← 1 2 3 4 5 6 7 →